111 Capital Invests $1.71 Million in Vertex Pharmaceuticals Incorporated $VRTX

111 Capital bought a new position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) in the 3rd quarter, according to its most recent disclosure with the SEC. The firm bought 4,363 shares of the pharmaceutical company’s stock, valued at approximately $1,709,000.

Other large investors have also recently modified their holdings of the company. Vanguard Group Inc. boosted its holdings in shares of Vertex Pharmaceuticals by 1.0% during the 3rd quarter. Vanguard Group Inc. now owns 24,216,865 shares of the pharmaceutical company’s stock valued at $9,484,293,000 after buying an additional 243,088 shares in the last quarter. Geode Capital Management LLC increased its stake in shares of Vertex Pharmaceuticals by 2.9% in the 2nd quarter. Geode Capital Management LLC now owns 5,928,747 shares of the pharmaceutical company’s stock worth $2,627,135,000 after acquiring an additional 166,987 shares in the last quarter. Alliancebernstein L.P. lifted its position in Vertex Pharmaceuticals by 10.7% during the 2nd quarter. Alliancebernstein L.P. now owns 4,378,320 shares of the pharmaceutical company’s stock valued at $1,949,228,000 after acquiring an additional 424,808 shares during the period. Loomis Sayles & Co. L P boosted its stake in Vertex Pharmaceuticals by 1.7% during the second quarter. Loomis Sayles & Co. L P now owns 3,813,378 shares of the pharmaceutical company’s stock worth $1,697,716,000 after acquiring an additional 65,047 shares in the last quarter. Finally, Norges Bank purchased a new stake in Vertex Pharmaceuticals in the second quarter worth about $1,593,974,000. Institutional investors own 90.96% of the company’s stock.

Trending Headlines about Vertex Pharmaceuticals

Here are the key news stories impacting Vertex Pharmaceuticals this week:

• Positive Sentiment: Clinical safety expansion — Vertex announced a new study to evaluate VX‑548 (an investigational pain drug) in breastfeeding women, broadening the drug’s safety profile and de‑risking development pathways if results are supportive. Vertex Expands VX‑548 Safety Profile With New Breastfeeding Study
• Positive Sentiment: Leadership/PR tailwind — TIME profiled CEO Reshma Kewalramani, reinforcing investor confidence in management’s execution and Vertex’s strategy to expand beyond cystic fibrosis. Physician‑Scientist Reshma Kewalramani Runs One of Biotech’s Biggest Companies
• Positive Sentiment: Analyst support — recent upgrades and raised price targets (several firms highlighted in coverage) help underpin the stock and attract buy‑side interest. MarketBeat VRTX analyst coverage
• Neutral Sentiment: Quarterly fundamentals — Q4 revenue rose ~9.5% y/y and margins remain strong, though EPS missed by $0.02 (reported $5.03 vs. $5.05 consensus); this is a small miss that keeps the longer‑term thesis intact but mutes near‑term upside. Vertex recent earnings summary
• Neutral Sentiment: Momentum/coverage — pieces asking whether VRTX is outperforming major indices may draw momentum flows but do not represent new fundamental catalysts. Is Vertex Stock Outperforming the Dow?
• Negative Sentiment: Clustered insider selling — multiple senior executives disclosed sales between Feb. 19–25, including a large sale by EVP Amit Sachdev (~58,613 shares, ~ $27.5M) and several other EVPs reducing positions. Such concentrated insider sales can create near‑term negative sentiment even if driven by diversification or tax planning. Representative SEC filing: SEC Form 4 – Amit Sachdev
• Negative Sentiment: Additional officer sale — CAO Kristen Ambrose sold 223 shares (minor relative to the EVP sales) but is part of the broader disclosure set that traders are reacting to. Vertex insider sales roundup

Insider Activity

In other Vertex Pharmaceuticals news, Chairman Jeffrey M. Leiden sold 63,781 shares of the company’s stock in a transaction that occurred on Wednesday, December 3rd. The shares were sold at an average price of $449.20, for a total value of $28,650,425.20. Following the completion of the transaction, the chairman directly owned 24,026 shares in the company, valued at $10,792,479.20. This represents a 72.64% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, EVP Ourania Tatsis sold 4,500 shares of the stock in a transaction on Wednesday, January 7th. The stock was sold at an average price of $474.99, for a total value of $2,137,455.00. Following the completion of the sale, the executive vice president owned 42,293 shares of the company’s stock, valued at $20,088,752.07. The trade was a 9.62% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders sold 168,937 shares of company stock worth $77,879,922. 0.20% of the stock is currently owned by corporate insiders.

Vertex Pharmaceuticals Stock Performance

NASDAQ VRTX opened at $496.83 on Monday. Vertex Pharmaceuticals Incorporated has a one year low of $362.50 and a one year high of $519.68. The stock has a 50-day moving average of $466.55 and a 200 day moving average of $432.55. The company has a market capitalization of $126.21 billion, a price-to-earnings ratio of 32.41 and a beta of 0.31.

Vertex Pharmaceuticals (NASDAQ:VRTX) last released its quarterly earnings results on Thursday, February 12th. The pharmaceutical company reported $5.03 earnings per share for the quarter, missing the consensus estimate of $5.05 by ($0.02). Vertex Pharmaceuticals had a net margin of 32.94% and a return on equity of 24.30%. The firm had revenue of $3.19 billion for the quarter, compared to the consensus estimate of $3.18 billion. During the same period in the previous year, the company earned $3.98 earnings per share. Vertex Pharmaceuticals’s quarterly revenue was up 9.5% compared to the same quarter last year. On average, equities analysts predict that Vertex Pharmaceuticals Incorporated will post 15.63 earnings per share for the current fiscal year.

Analyst Ratings Changes

VRTX has been the subject of several recent research reports. HC Wainwright set a $591.00 target price on shares of Vertex Pharmaceuticals in a report on Tuesday, February 17th. Leerink Partners upped their price target on Vertex Pharmaceuticals from $456.00 to $525.00 and gave the stock an “outperform” rating in a research note on Monday, December 29th. Cantor Fitzgerald reiterated an “overweight” rating and set a $590.00 price objective on shares of Vertex Pharmaceuticals in a research note on Friday, February 13th. Canaccord Genuity Group boosted their target price on Vertex Pharmaceuticals from $411.00 to $441.00 and gave the stock a “hold” rating in a report on Tuesday, February 17th. Finally, Scotiabank increased their target price on Vertex Pharmaceuticals from $495.00 to $558.00 and gave the stock an “outperform” rating in a research note on Friday, February 13th. Twenty-two investment analysts have rated the stock with a Buy rating and five have issued a Hold rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $542.00.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Inc is a Boston-based biotechnology company focused on the discovery, development and commercialization of therapies for serious diseases. Founded in 1989, Vertex built its reputation on research-driven drug development and is best known for its work in cystic fibrosis (CF), where its portfolio of small-molecule CFTR modulators transformed standards of care for many people with the disease. The company operates research and development, manufacturing and commercial organizations and serves patients and healthcare systems in multiple international markets.

Vertex’s marketed products center on CFTR modulators that target the underlying cause of cystic fibrosis rather than just treating symptoms.